What is Azure Biosystems?
Headquartered in California, Azure Biosystems operates as a pivotal player in the development and commercialization of high-performance analytical tools. The company specializes in a comprehensive suite of life science research solutions, including advanced imaging systems, quantitative PCR (qPCR) platforms, and specialized reagents. By focusing on the intersection of cell analysis, genomics, and protein biology, Azure Biosystems provides essential infrastructure for academic institutions and private research organizations. Their business model emphasizes the delivery of affordable, high-quality instrumentation, effectively democratizing access to sophisticated diagnostic and experimental capabilities for scientists worldwide.
How much funding has Azure Biosystems raised?
Azure Biosystems has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Azure Biosystems
PPP
Public-Private Partnership
What's next for Azure Biosystems?
Following this late-stage financing, Azure Biosystems is expected to prioritize the expansion of its R&D pipeline and the optimization of its global supply chain. The strategic allocation of these funds will likely facilitate the introduction of next-generation imaging technologies and the scaling of its reagent manufacturing capacity. As the company transitions into this growth phase, the focus will remain on maintaining its competitive edge in the life sciences market while addressing the evolving needs of the genomics and proteomics research communities. This capital infusion serves as a catalyst for long-term innovation and market leadership.
See full Azure Biosystems company page
